Roxana Stefania Dronca
Mayo Clinic · 246 works · 13,733 citations · h-index 41
Top works
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
- Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
- Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab
- Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL).
- Programmed Death-Ligand 1 Expression and Response to the Anti–Programmed Death 1 Antibody Pembrolizumab in Melanoma
- Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001
- Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma
- Evaluation of immune-related response criteria (irRC) in patients (pts) with advanced melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475.
- Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab
- Long-term efficacy of pembrolizumab (pembro; MK-3475) in a pooled analysis of 655 patients (pts) with advanced melanoma (MEL) enrolled in KEYNOTE-001.
- Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer
- Three-year overall survival for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001.
- Clinical efficacy and correlation with tumor PD-L1 expression in patients (pts) with melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475.
- Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma
- The use of pembrolizumab for the treatment of metastatic uveal melanoma
- 1139P Long-term safety profile of pembrolizumab monotherapy and relationship with clinical outcome: A pooled analysis of patients with advanced melanoma
- NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2024
- 5-year survival outcomes in patients (pts) with advanced melanoma treated with pembrolizumab (pembro) in KEYNOTE-001.
- Abstract CT104: Antitumor activity of the anti-PD-1 monoclonal antibody MK-3475 in melanoma(MEL): Correlation of tumor PD-L1 expression with outcome